Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, Ravulizumab can be used for the researchs of COVID-19-associated severe pneumonia, acute lung injury and acute respiratory distress syndrome.
Purity:
>95.0%
CAS Number:
[1803171-55-2]
Target:
Complement System
* VAT and and shipping costs not included. Errors and price changes excepted
